This article is more than 5 years old. Information may no longer be current.
Stent graft receives FDA approval, CE mark for treatment of abdominal aortic aneurysm
Click Here to Manage Email Alerts
Medtronic announced that it has received both FDA approval and a CE mark for its Endurant IIs AAA stent graft, intended for minimally invasive treatment of abdominal aortic aneurysms.
According to a press release, the device features a 50 mm ipsilateral leg, allowing for more flexibility in targeted limb placement; and equal leg diameters, enabling the use of limbs on either side. For select ipsilateral limbs, the graft allows for a three to five stent overlap for adjustment during implantation.
The Endurant IIs graft serves as a bifurcated component within the Endurant AAA stent graft system, allowing for increased anatomical customization options, according to the release. It is intended to complement the Endurant II graft, and utilizes the same delivery system, but has a distal diameter up to 20% smaller than select Endurant II grafts.
“Every [abdominal aortic aneurysm] patient has different anatomical features, which is why it’s so important for a stent graft system to provide for a wide variety of anatomical customization options,” William D. Jordan, Jr., MD, professor of surgery and chief of vascular surgery and endovascular therapy at the University of Alabama Birmingham, said in the release.